" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific, GMU, Johns Hopkins and Toronto’s UHN Extend Collaboration

Published: Wednesday, March 31, 2010
Last Updated: Wednesday, March 31, 2010
Bookmark and Share
Accelerating biomarker identification for cancer and other diseases may speed development of diagnostic tests that enable earlier disease detection.

Thermo Fisher Scientific Inc., has announced that its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has extended its groundbreaking collaboration with George Mason University’s Center for Applied Proteomics and Molecular Medicine (CAPMM), Johns Hopkins University and Toronto’s University Health Network (UHN).

For the past two years, these organizations have collaborated with BRIMS to accelerate the verification and validation of protein biomarkers for cancer and other diseases.

For years, biomarker researchers sought independent validation of putative biomarkers and routine, mass spectrometry-based quantitative assays suited for the rigors of clinical research.

Thermo Fisher’s BRIMS Center addressed these challenges by developing targeted SRM-based quantitative mass spectrometry workflows that enable rapid assay development and cross validation of biomarker assays across the network of laboratories. Each of the collaborators uses these biomarkers and assays as they perform research on identical Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer platforms.  

“Working together, the BRIMS Center and the collaborators demonstrated an instrument platform and an end-to-end workflow from sample preparation through data analysis that are easily and reproducibly transferred from laboratory to laboratory,” said Mary Lopez, director, BRIMS Center. “By continuing our work with these leading research groups, we can extend their ground-breaking research by continuing to apply the SRM-based workflow to previously validated clinical biomarkers.”

“Together, we’ve taken a remarkable step forward by combining the BRIMS Center’s expertise in workflow development, state-of-the-art Thermo Scientific technologies and the talent of leading researchers with valuable clinical expertise,” said Iain Mylchreest, vice president and general manager, life science mass spectrometry, Thermo Fisher Scientific. “By delivering reproducible, quantitative verification and validation of protein biomarkers in a clinical research setting, the researchers are now that much closer to their goal of developing tests for cancer.”

Members of the collaboration team presented their results, an inter-lab reproducibility study, at the U.S. Human Proteome Organization 2010 meeting, March 7-10, in Denver, Colorado.

The study is the first inter-lab study to demonstrate reproducible determination of protein abundance in a complex matrix such as blood. The study also demonstrated that an optimized biomarker assay can be implemented relatively quickly across several laboratories without need for additional optimization.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Scientific Receives IVDD CE Mark for LC-MS Products
Now available to clinical laboratories in Europe for general in vitro diagnostic use.
Friday, September 11, 2015
Ebola Sequencing Data Released to Global Research Community Online
To curb further spread of Ebola in Sierra Leone, a team of scientists that is part of an international, multi-organizational effort has released their first dataset of the virus’ genetic structure online.
Wednesday, June 03, 2015
Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo Scientific Announces Listing of the Ion PGM Dx System
Company has completed the listing with the U.S. FDA as class II medical device.
Saturday, September 20, 2014
Thermo Registers San Jose Facility with FDA
The site has established a quality system in accordance with the FDA Quality System Regulations to design and manufacture devices for analyzing samples from patients for in vitro diagnostic use.
Monday, June 16, 2014
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo Acquires Prionics AG
Thermo Fisher Scientific announce it has completed the acquisition of Prionics AG, a privately held animal health diagnostics company.
Monday, March 17, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
One Lambda Receives CE Mark Approval for C1qScreen
Assay cited in New England Journal of Medicine for use in determining impact on kidney graft survival.
Tuesday, November 19, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Scientific Enters into a Long-Term Agreement with Fujirebio
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.
Thursday, November 22, 2012
Thermo Fisher Scientific Completes Acquisition of One Lambda
The business will become part of Thermo Fisher’s Specialty Diagnostics Segment.
Friday, September 14, 2012
Thermo Scientific Ensures Patient Safety with Solution to Label and Track Tissue Samples in Pathology Laboratories
The new solutions include SlideMate on-demand slide printer and the PrintMate automated cassette printing system.
Thursday, April 22, 2010
Thermo Fisher Scientific Opens New UK Facility for Cancer Diagnostics and Chromatography Products
The new facility houses Thermo Fisher’s Anatomical Pathology and Chromatography Consumables businesses.
Thursday, February 11, 2010
Scientific News
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!